ArticleThe Clinical journal of pain2022

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.

Karissa M Johnston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.